Authors: B Abrahamsen T van Staa R Ariely M Olson C Cooper
Publish Date: 2009/05/07
Volume: 20, Issue: 10, Pages: 1633-1650
Abstract
Summary This systematic literature review has shown that patients experiencing hip fracture after lowimpact trauma are at considerable excess risk for death compared with nonhip fracture/community control populations The increased mortality risk may persist for several years thereafter highlighting the need for interventions to reduce this riskPatients experiencing hip fracture after lowimpact trauma are at considerable risk for subsequent osteoporotic fractures and premature death We conducted a systematic review of the literature to identify all studies that reported unadjusted and excess mortality rates for hip fracture Although a lack of consistent study design precluded any formal metaanalysis or pooled analysis of the data we have shown that hip fracture is associated with excess mortality over and above mortality rates in nonhip fracture/community control populations during the first year after fracture ranging from 84 to 36 In the identified studies individuals experienced an increased relative risk for mortality following hip fracture that was at least double that for the agematched control population became less pronounced with advancing age was higher among men than women regardless of age was highest in the days and weeks following the index fracture and remained elevated for months and perhaps even years following the index fracture These observations show that patients are at increased risk for premature death for many years after a fragilityrelated hip fracture and highlight the need to identify those patients who are candidates for interventions to reduce their riskB Abrahamsen receives consultancy fees from Nycomed and Novartis and research grants from Roche TP van Staa works for the General Practice Research Database GPRD which is owned by the UK Department of Health and operates within the Medicines and Healthcare products Regulatory Agency MHRA GPRD is funded by the MHRA Medical Research Council various universities contract research organizations and pharmaceutical companies C Cooper has no conflict of interest to declare R Ariely is an employee of Novartis Pharmaceutical Corporation M Olson is an employee of Novartis Pharma AG
Keywords: